Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoGenex Technologies has reported that OGX-011 or custirsen was well-tolerated in combination with either docetaxel or mitoxantrone administered as second-line chemotherapy in patients with hormone refractory prostate cancer.
Subscribe to our email newsletter
This Phase II study was designed as an open-label, randomized, multicenter study evaluating weekly administration of OGX-011 in combination with second-line chemotherapy. According to data the primary objectives of safety and tolerability were achieved in the 42 patients evaluated in the study. Additionally, patients treated with second-line chemotherapy plus OGX-011 showed ongoing survival durations better than results published with chemotherapy alone.
Fred Saad, primary investigator in the study, said: “The data suggests that retreatment with docetaxel when combined with OGX-011 may reverse chemotherapy resistance in second-line docetaxel retreatment. We look forward to confirming these data in planned Phase III studies.”